Bevacizumab plus capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients with metastatic colorectal cancer (mCRC) suitable for combination chemotherapy: Efficacy and safety findings from the phase II BECOX study (GEMCAD Study Gro
Fecha de publicación
2013Título de revista
EUROPEAN JOURNAL OF CANCER
Tipo de contenido
Artigo